Physician profile
Jayalekshmy B Kumar
NPI 1184658825
$23,383.19
in general payments reported to CMS, 2019-2025
72 companies · $4,482 in 2025
The $4,482 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,751 · 2020: $1,561 · 2021: $2,418 · 2022: $3,563 · 2023: $4,204 · 2024: $4,404 · 2025: $4,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,969.84 |
| Education | $120.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,625.03 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,430.78 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $1,418.62 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,358.68 | 2019-2025 | |
| Ucb, INC. | $1,353.43 | 2019-2025 | Briviact, Zilbrysq, Rystiggo |
| Lundbeck LLC | $1,000.72 | 2021-2025 | Vyepti, Rexulti |
| Biogen, INC. | $948.36 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Eisai INC. | $943.93 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $846.31 | 2019-2025 | Ongentys, Rytary, Crexont |
| Emd Serono, INC. | $755.80 | 2019-2025 | Mavenclad |
| Csl Behring | $734.47 | 2019-2025 | Hizentra |
| Sk Life Science, INC. | $687.64 | 2021-2025 | Xcopri |
| Sunovion Pharmaceuticals INC. | $616.09 | 2020-2022 | |
| Lilly USA, LLC | $594.31 | 2019-2025 | Reyvow, Emgality, Kisunla |
| Genzyme Corporation | $509.41 | 2019-2025 |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayalekshmy Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.